| gap-debate-20260410- | How do NAD+ depletion kinetics differ between APOE3 and APOE4 microglia under ne | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-debate-20260410- | What is the mechanistic relationship between APOE4-induced lipid droplet accumul | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | Which specific metabolic pathways in APOE4 microglia are causally linked to dysf | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which ADCY8 variants specifically enhance versus impair spatial memory consolida | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-genetics |
| gap-debate-20260410- | How does ADCY8 coupling with circadian clock genes mechanistically regulate time | open | 0.75 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | What are the specific molecular mechanisms linking ADCY8 to spatial memory conso | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-pubmed-20260410- | What is the causal relationship between HCN1 alteration and epileptogenesis? | open | 0.82 | 0.00 | 2026-04-10 | 0 | | epilepsy |
| gap-pubmed-20260410- | Why does blocking Ih current show antiepileptic effects in vivo despite increasi | open | 0.85 | 0.00 | 2026-04-10 | 0 | | epilepsy |
| gap-pubmed-20260410- | How do HCN channels' opposite effects on cellular vs network excitability reconc | open | 0.72 | 0.00 | 2026-04-10 | 0 | | epilepsyseizure-mechanisms |
| gap-pubmed-20260410- | What are the detailed mechanisms by which different HCN isoforms modulate absenc | open | 0.78 | 0.00 | 2026-04-10 | 0 | | epilepsyseizure-mechanisms |
| gap-pubmed-20260410- | Why do HCN1/HCN2 knockouts promote seizures while pan-HCN blockers suppress them | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | epilepsyseizure-mechanisms |
| gap-pubmed-20260410- | Do other HCN1 epilepsy mutations beyond M305L and D401H respond to propofol resc | open | 0.82 | 0.00 | 2026-04-10 | 0 | | channelopathy |
| gap-pubmed-20260410- | Can the methionine-phenylalanine interface be exploited to design HCN1-specific | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does propofol binding at the S5-S6 interface stabilize voltage sensor-pore c | open | 0.84 | 0.00 | 2026-04-10 | 0 | | channelopathy |
| gap-pubmed-20260410- | How does Reelin processing into fragments regulate specific signaling functions | open | 0.81 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What determines which downstream effectors are recruited for specific Reelin fun | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What determines the penetrance and expressivity of protective genetic variants a | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can the heparan-sulphate proteoglycan-APOE receptor pathway be therapeutical | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do protective variants in APOE and RELN mechanistically confer cognitive res | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the downstream signaling pathways linking ARF6/exocyst to VE-cadherin t | open | 0.56 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-pubmed-20260410- | How does VE-cadherin mechanistically control reelin secretion from lymphatic end | open | 0.64 | 0.00 | 2026-04-10 | 0 | | vascular-biology |
| gap-pubmed-20260410- | How does endothelial CD2AP loss specifically contribute to neurodegeneration ver | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the sex-dependent differences in cerebrovascu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cerebrovascular-biology |
| gap-debate-20260410- | What determines glycocalyx-mediated selectivity for different misfolded protein | open | 0.65 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can cellular stress response pathways distinguish between protective and patholo | open | 0.73 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | How do pathological proteins hijack endogenous chaperone networks during interce | open | 0.78 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Do different misfolded proteins require specific tunneling nanotube diameters fo | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can microglial polarization states selectively target excitatory vs inhibitory s | open | 0.69 | 0.00 | 2026-04-10 | 0 | | synaptic-neurobiology |
| gap-debate-20260410- | How do reactive astrocytes regulate local complement activity in different hippo | open | 0.71 | 0.00 | 2026-04-10 | 0 | | glial-biology |
| gap-debate-20260410- | What is the temporal sequence of complement activation phases that produce disti | open | 0.78 | 0.00 | 2026-04-10 | 0 | | behavioral-neuroscience |
| gap-debate-20260410- | Do hippocampal circuits express distinct complement receptor profiles that deter | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | How do brain-penetrant SPI1 modulators affect essential myeloid cell functions v | open | 0.71 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | Which SPI1-regulated metabolic pathways specifically sustain chronic neuroinflam | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | What are the temporal dynamics of SPI1 activity during microglial state transiti | open | 0.78 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-debate-20260410- | Does SPI1 directly bind and regulate C1Q promoter regions in brain microglia ver | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | How do tissue-specific senescence patterns affect the universal applicability of | open | 0.70 | 0.00 | 2026-04-10 | 0 | | translational-medicine |
| gap-debate-20260410- | How do microglial state transitions determine whether TNF-α/IL-6 signaling is pr | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do Cdk5/p35/p39 mutations affect both nucleokinesis and leading edge formati | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What are the precise molecular mechanisms by which LIS1 and doublecortin regulat | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How does Reelin trigger recognition-adhesion among target neurons to form archit | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What determines whether leading edge extension proceeds via axonal growth cones | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How do Cdk5/p35/p39 mutations affect both nucleokinesis and leading edge formati | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What is the molecular mechanism by which Reelin triggers recognition-adhesion am | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How do PGC1α's multiple functions (mitochondrial biogenesis, ROS regulation, inf | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is PGC1α expression specifically reduced in AD brains compared to other neur | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which PGC1α regulates BACE1 expres | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does PGC-1α loss-induced PV+ interneuron dysfunction contribute to circuit-l | open | 0.81 | 0.00 | 2026-04-10 | 0 | | circuit-dysfunction |
| gap-pubmed-20260410- | How does neuronal activity specifically trigger PGC-1α activation in PV+ interne | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How do endogenous CNS ligands activate PPAR-γ pathways and what determines their | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which PPAR-γ agonists regulate neu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |